탄자니아 - 영어 - Tanzania Medicinces & Medical Devices Authority

moraf pharmaceuticals limited, tanzania - shoulder support -

미국 - 영어 - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] •have not provided adequate analgesia, or are not expected to provide adequate analgesia •have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated for: - all children younger than 12 years of age (see warnings ). - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see warnings ).  acetaminophen and codeine phosphate tablets are contraindicated in patients wit

몰타 - 영어 - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

몰타 - 영어 - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - lactobacillus plantarum, quantity: 4.5 billion cfu; lactobacillus casei, quantity: 10 billion cfu; lactobacillus acidophilus, quantity: 11 billion cfu; lactobacillus delbrueckii ssp bulgaricus, quantity: 1 billion cfu; lactobacillus paracasei, quantity: 2.5 billion cfu; bifidobacterium animalis ssp lactis, quantity: 1 billion cfu - capsule, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; gellan gum - maintain/support general health and wellbeing ; maintain/support intestinal health ; maintain/support intestinal good/beneficial/friendly flora ; maintain/support gastrointestinal system health ; maintain/support gastrointestinal mucosal membrane health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy gastrointestinal immune function

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals pty ltd - calcium orotate, quantity: 80.6 mg (equivalent: calcium, qty 10 mg); calcium hydrogen phosphate dihydrate, quantity: 146 mg (equivalent: calcium, qty 34 mg); potassium aspartate monohydrate, quantity: 242 mg (equivalent: potassium, qty 50 mg); magnesium orotate dihydrate, quantity: 457 mg (equivalent: magnesium, qty 30 mg); magnesium aspartate dihydrate, quantity: 280.35 mg (equivalent: magnesium, qty 21 mg) - tablet, film coated - excipient ingredients: carnauba wax; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; purified talc; croscarmellose sodium; hypromellose; macrogol 3350; chlorophyllin-copper complex - maintain/support energy production ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; helps maintain/support vasodilator/ blood vessel dilation ; maintain/support blood vessel health ; maintain/support healthy muscle contraction function ; maintain/support muscle function ; maintain/support healthy neuromuscular system/function ; maintain/support muscle relaxation ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support nerve conduction ; maintain/support nervous system function

미국 - 영어 - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied

미국 - 영어 - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate tablets, usp are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. zolpidem tartrate tablets, usp have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [ see clinical studies (14)] . the clinical trials performed in support of efficacy were 4 to 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. zolpidem tartrate tablets are contraindicated in patients zolpidem tartrate tablets are contraindicated in patients - who have experienced complex sleep behaviors after taking zolpidem tartrate tablets [see warnings and precautions ( 5.1)]. who have experienced complex sleep behaviors after taking zolpidem tartrate tablets

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sigma company limited - pyridoxine hydrochloride, quantity: 25 mg (equivalent: pyridoxine, qty 20.57 mg); riboflavin, quantity: 10 mg; passiflora incarnata, quantity: 12.5 mg (equivalent: passiflora incarnata, qty 50 mg); calcium ascorbate dihydrate, quantity: 167.42 mg (equivalent: ascorbic acid, qty 137.45 mg); calcium pantothenate, quantity: 50 mg (equivalent: pantothenic acid, qty 45 mg); valeriana officinalis, quantity: 5 mg (equivalent: valeriana officinalis, qty 20 mg); nicotinamide, quantity: 50 mg; magnesium phosphate tribasic, quantity: 130 mg (equivalent: magnesium, qty 26.8 mg); ascorbic acid, quantity: 137.55 mg; folic acid, quantity: 20 microgram; biotin, quantity: 20 microgram; lecithin, quantity: 50 mg; d-alpha-tocopheryl acid succinate, quantity: 21.56 mg; inositol, quantity: 25 mg; thiamine hydrochloride, quantity: 50 mg; choline bitartrate, quantity: 25 mg; cyanocobalamin, quantity: 25 microgram; monobasic potassium phosphate, quantity: 62.65 mg (equivalent: potassium, qty 18 mg) - tablet, film coated - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; hypromellose; colloidal anhydrous silica; titanium dioxide; crospovidone; macrogol 8000; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; magnesium stearate - maintain/support energy levels ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; decrease/reduce/relieve symptoms of stress ; maintain/support general mental wellbeing ; maintain/support nervous system health

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.